Anadys Pharmaceuticals, Inc. (the "Company") is reporting that enrollment has been completed in the Phase IIb study of setrobuvir (ANA598), in which setrobuvir is being tested in combination with pegylated interferon and ribavirin in hepatitis C patients. The Company anticipates that all patients in the study will have completed their 12 week visit by the end of the third quarter of 2011 and plans to release preliminary 12 week data shortly thereafter.
Read More;
http://www.morningstar.co.uk/uk/markets/newsfeeditem.aspx?id=148573656361296
July 07, 2011 17:07 ET (21:07 GMT)
Copyright (c) 2011 Dow Jones & Company, Inc.
No comments:
Post a Comment